Your session is about to expire
← Back to Search
MRTX849 + Pembrolizumab for Non-Small Cell Lung Cancer with KRAS G12C Mutation
This trial is testing a new cancer drug, MRTX849, to see if it is effective in treating patients with advanced lung cancer who have a specific gene mutation.
- Non-Small Cell Lung Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
- Group 1: Phase 3 Cohort 3 Investigational Arm
- Group 2: Phase 3 Cohort 4 Comparator Arm
- Group 3: Phase 2 Cohort 1a: PD-L1 TPS <1%
- Group 4: Phase 2 Cohort 1b: PD-L1 TPS <1%
- Group 5: Phase 2 Cohort 2: PD-L1 TPS ≥1%
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there openings for participants in this experiment?
"According to clinicaltrials.gov, this trial is presently seeking participants with enrollment commencing December 2nd 2020 and the latest update occurring November 21st 2022."
How many locations are participating in the implementation of this clinical trial?
"At this time, 90 clinical trial sites are actively recruiting patients. Locations include Richmond, Covington, and Las Vegas - among many other locales. To minimize the potential for travel obligations, it is ideal to select a location closest to you if participation in the study is desired."
What medical conditions are MRTX849 in Combination with Pembrolizumab typically prescribed for?
"The antiviral MRTX849, when administered in conjunction with pembrolizumab, is sometimes used to combat malignant neoplasms. Additional conditions that this treatment combination can be employed for include unresectable melanoma, microsatellite instability high and progression of disease after chemotherapy has been attempted."
What objectives is this research endeavor attempting to reach?
"According to the trial sponsor, Mirati Therapeutics Inc., this clinical study will measure primary outcomes over a 22 month period, including Evaluating the efficacy of MRTX849 in combination with pembrolizumab. Secondary objectives are assessing safety profiles and pharmacokinetic characteristics of MRTX849 when administered as monotherapy or combined with pembrolizumab and measuring duration of response."
Has the FDA authorized MRTX849 coupled with Pembrolizumab for medical use?
"The safety of using MRTX849 alongside pembrolizumab has been supported by preliminary clinical data and thus, it receives a score of 2."
How many individuals are receiving treatment within this research program?
"The trial necessitates 250 eligible patients. Those looking to join can seek the trial out of locations like Virginia Cancer Institute in Richmond, VA and Pontchartrain Cancer Center - Covington Office in Covington, LA."
What other experiments have examined the effects of MRTX849 in tandem with Pembrolizumab?
"Currently, there are 965 medical trials assessing the effects of MRTX849 in Combination with Pembrolizumab; 124 of which have reached Phase 3. Houston, Texas is at the focal point for these investigations and 36174 sites around the world participate in this research."
Share this study with friends